Lenvatinib Mesylate Capsules Receive Drug Registration Certificate
August 10, 2026
Source: drugdu
29
Nanfang Finance News, August 7th - Lu Kang PharmaceuticalThe company announced that it has received a Drug Registration Certificate for Lenvatinib Mesylate Capsules issued by the National Medical Products Administration. This product is used to treat patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.
https://finance.eastmoney.com/a/202608073835336556.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap August 10, 2026
- Vonoprazan Fumarate Tablets Receive Drug Registration Certificate August 10, 2026
- Loxoprofen Sodium Patch Receives Drug Registration Certificate August 10, 2026
- Subsidiary obtains drug registration certificate for injectable multivitamins (12) August 10, 2026
- its stock price has shrunk by 90% from its issue price, and although it has finally received approval for its first product, the market landscape has already changed. August 4, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
